The DNA damage response (DDR) field has seen major advances in recent years, particularly in ovarian, breast, prostate, and pancreatic cancers. Most cancers depend on DNA damage detection and repair for survival and are thus vulnerable to targeted inhibition of DDR proteins. DDR therapies include inhibitors of PARP, ATR, WEE1, and DNA-PK. The DDR field is rapidly evolving with new agents and unique combinations of MOAs in active development.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in DDR therapies to help guide strategic and tactical commercial development decisions for market participants.